ElsaLys Biotech, a Lyon & Illkirch Graffenstaden-France-based developer of therapeutic monoclonal antibodies, raised €2.1m in its first round of financing.
Backers included biopharmaceutical company Transgene (NYSE-Euronext: TNG) and Sofimac Partners.
The company intends to use the capital to develop antibodies against targets derived from academic collaborators up to characterized drug candidates with in vivo proof of concept. Further clinical development will be conducted through industrial partnerships.
Co-founded by Dr Jean-Yves Bonnefoy, CEO, and Dr Christine Guillen, formerly Manager of External R&D collaborations at Transgene, COO, ElsaLys Biotech is an R&D start-up focused on converting therapeutic targets into exploitable drug candidates. The portfolio of the company includes 4 novel projects issued from academic groups and partners such as EFS, Curie Institute, Tumor Institute of Turin and SATT-Sud Est.
FinSMEs
17/05/2013